By Sahithya K · Reviewed by Divya Chandradhara · Published 16 November 2026

Choosing a contract research organisation, or CRO, in India starts with fixing the scope of work, then scoring each candidate on regulatory standing, therapeutic fit, sites, data systems, quality history, staffing, project management, commercial terms and communication. The sponsor keeps legal responsibility for the trial whatever it outsources, so the evaluation is also a test of how well the sponsor can oversee the CRO.

Why CRO selection matters: the sponsor keeps responsibility

A sponsor can transfer trial work to a CRO but cannot transfer responsibility for it. ICH E6(R3), the current ICH good clinical practice guideline, states in its tenth principle that where activities are transferred to service providers, responsibility for the conduct of the trial, including the quality and integrity of the data, stays with the sponsor. The sponsor must also maintain appropriate oversight of the transferred work.

Indian law places the core obligations on the party holding the trial permission. Under the New Drugs and Clinical Trials Rules, 2019, the sponsor or its representative that obtained permission carries the compensation and medical management obligations for trial-related injury, and the Clinical Trials Registry – India holds the primary sponsor ultimately accountable for registering the trial. A weak CRO does not dilute those obligations. It makes them harder to meet.

Step 1: define the outsourcing scope (full-service, FSP or functional)

The scope decides which CROs are relevant at all, so it is fixed before the first conversation. Three outsourcing models are common:

  • Full-service: the CRO runs the trial end to end, from regulatory submission and site start-up through monitoring, data management, biostatistics and the clinical study report.

  • Functional service provider (FSP): the CRO supplies a defined function, such as monitoring or data management, inside the sponsor’s own processes and systems.

  • Functional or task-based: discrete deliverables, such as an ethics committee submission package, a statistical analysis plan or a medical writing assignment.

The scope statement also records the phase, the therapeutic area, the number of sites expected, the target population and the deliverables the sponsor needs at the end. A CRO asked to quote against a vague scope will quote against its own assumptions, and those assumptions are hard to compare across bidders.

Step 2: score CROs on nine evaluation criteria

Table 1. The nine evaluation dimensions

#DimensionWhat to check
1Regulatory standingRegistration with the Central Drugs Standard Control Organisation where applicable, quality certifications and experience of submissions under the NDCT Rules
2Therapeutic fitTrials completed in the same therapeutic area and phase, and the investigators and endpoints involved
3Site and investigator networkSites with registered ethics committees, recruitment history in the target population and realistic enrolment rates
4Data systemsElectronic data capture, validation of computerised systems, audit trails and data governance
5Quality and inspection historyAudit findings, inspection outcomes, CAPA records and how the CRO handled a serious deviation
6Staffing model and turnoverNamed team, their experience, how many trials each person carries and how replacements are handled
7Project management structureOne accountable project lead, escalation routes and how changes in scope are controlled
8Commercial termsPrice build-up, pass-through costs, payment milestones and how change orders are priced
9Communication cadenceReporting frequency, the format of status reports and access to live trial data

Not every dimension favours the same kind of CRO. A large multinational CRO usually scores higher on site network breadth and system scale. A specialist CRO may score higher on therapeutic depth, senior attention and flexibility. A framework that ignores the dimensions a candidate is weak on is a sales document, not an evaluation.

Step 3: build a weighted CRO scoring matrix

The matrix below turns the nine dimensions into a comparable score. The sponsor sets the weights before seeing any proposals, so that the weighting reflects the trial rather than the most persuasive presentation.

Table 2. A scoring matrix sponsors can complete

DimensionWeight (sponsor sets, total 100)CRO A score (1 to 5)CRO B score (1 to 5)CRO C score (1 to 5)
Regulatory standing
Therapeutic fit
Site and investigator network
Data systems
Quality and inspection history
Staffing model and turnover
Project management structure
Commercial terms
Communication cadence
Weighted total100

Each score is multiplied by its weight, and the weighted scores are added. Evidence for every score is written down, because a score that cannot be traced to a document or a reference call will not survive the sponsor’s own quality review.

Step 4: questions to ask a CRO before shortlisting

A capability call is useful only if the questions require evidence rather than description. The questions that separate candidates most clearly are these:

  • Which trials in this therapeutic area and phase has the CRO completed in the last three years, and can it share anonymised enrolment curves for them?

  • Who will be the named project lead and lead monitor, and how many other trials are they assigned to?

  • What were the findings of the CRO’s most recent sponsor audit or regulatory inspection, and what corrective actions followed?

  • How does the CRO validate its computerised systems, and can it show the audit trail for a corrected data point?

  • How does the CRO meet the twenty-four-hour serious adverse event reporting requirement at its sites, and how is it tracked?

  • Which ethics committees will review the protocol, and are their registrations current?

  • Which activities would be subcontracted, to whom and how would the sponsor oversee them?

  • How are change orders priced, and what triggered change orders on recent comparable trials?

Step 5: write a CRO RFP that makes proposals comparable

A request for proposal works when every bidder answers the same questions against the same assumptions. An RFP for a clinical trial in India normally contains:

  • the protocol synopsis, phase, indication and target population

  • the number of sites and subjects assumed, and the planned recruitment period

  • the scope matrix, showing which activities sit with the CRO and which with the sponsor

  • the regulatory route expected under the NDCT Rules and the documents the CRO is to prepare

  • the data management, biostatistics and medical writing deliverables, including the clinical study report

  • the quality requirements, including audit rights and inspection support

  • a pricing template with unit costs, pass-through costs and payment milestones

  • the evaluation criteria and weights, so bidders know how they will be judged

Asking every bidder to price against the same template is the single change that most improves comparability, because it stops each proposal from defining the work differently.

Red flags when evaluating a CRO

Some signals justify removing a candidate regardless of score:

  • No named team until after contract signature.

  • Enrolment projections with no supporting site data.

  • Reluctance to share audit or inspection findings under a confidentiality agreement.

  • A price far below the other bids with no explanation of the difference.

  • Unclear subcontracting, especially of monitoring or data management.

  • Claims of superlative standing that cannot be checked, in place of verifiable registrations and certifications.

  • No clear answer on who prepares and submits the serious adverse event reports and within what period.

CRO oversight after selection

Selection ends with an agreement, and under ICH E6(R3) the agreement must define the roles, activities and responsibilities of each party. The oversight plan belongs in the same document: what the sponsor will review, how often, what triggers escalation and how audit rights are exercised. A CRO that resists a clear oversight plan at contract stage is unlikely to welcome it later.

BioAgile’s clinical research services for pharmaceutical and nutraceutical sponsors are offered under CDSCO Reg. CRO/KA/2026/000173 and ISO 9001:2015 certification, and sponsors evaluating CROs can request BioAgile’s responses to every question above through the enquiry form.

Questions sponsors ask about choosing a CRO

What should I look for when choosing a CRO in India?

Look at nine dimensions: regulatory standing, therapeutic fit, site and investigator network, data systems, quality and inspection history, staffing model and turnover, project management structure, commercial terms and communication cadence. Weight them for the specific trial before reading any proposals, and score each candidate on documented evidence rather than presentations.

What is the difference between a full-service CRO and an FSP?

A full-service CRO runs the trial end to end, from regulatory submission to the clinical study report. A functional service provider supplies a defined function, such as monitoring or data management, inside the sponsor’s own processes and systems. The right model depends on how much internal capacity and process the sponsor already has.

Does the sponsor remain responsible if a CRO runs the trial?

Yes. ICH E6(R3) states that a sponsor may transfer tasks to a service provider but keeps overall responsibility, including for the quality and integrity of the data. Under the NDCT Rules, the sponsor or its representative holding the permission also carries the compensation and medical management obligations for trial-related injury.

What should a CRO RFP include?

The protocol synopsis, assumed sites and subjects, a scope matrix, the expected regulatory route, the data and reporting deliverables, quality and audit requirements, a common pricing template and the evaluation criteria with their weights. A common pricing template matters most, because it stops each bidder from defining the work differently.

How many CROs should be shortlisted?

Most sponsors send an RFP to a small number of candidates that already meet the scope and regulatory requirements, typically three to five. Fewer limits comparison, and many more makes a careful evaluation of evidence, reference calls and capability discussions difficult to complete within a realistic start-up timeline.

What are the warning signs of an unsuitable CRO?

No named team before signature, enrolment projections without site data, reluctance to share audit findings, an unexplained low price, unclear subcontracting and claims of standing that cannot be verified. Any one of these justifies a direct follow-up question, and an unsatisfactory answer justifies removing the candidate from the shortlist.

About this guide

This guide draws on ICH E6(R3), Guideline for Good Clinical Practice, adopted on 6 January 2025, and on the New Drugs and Clinical Trials Rules, 2019. It was written by Sahithya K, and reviewed by Divya Chandradhara It states the position as at 16 November 2026 and is reviewed every twelve months.